专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明公开

EP2266946A3 Compound For The Treatment Of Metabolic Disorders 审中-公开
标题翻译：化合物的代谢障碍的治疗
公开(公告)号：EP2266946A3
公开(公告)日：2012-12-12
申请号：EP10184293.8
申请日：2004-02-09
申请人： Wellstat Therapeutics Corporation
发明人： Hodge, Kirvin , Lee, Albert , Sharma, Shalini , Von Borstel, Reid
IPC分类号： C07C69/734 , C07C59/64 , C07C59/68 , C07C65/24 , A61K31/192 , A61K31/24 , A61P3/10 , A61P3/00 , C07C69/76 , C07C69/92
CPC分类号： C07C69/734 , A61K31/192 , A61K31/24 , C07C59/68 , C07C65/24 , C07C69/76 , C07C69/92
摘要： Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed.

wherein n is 1 or 2; m is 0, 1, 2, 4, or 5; q is 0 or 1; t is 0 or 1; R 2 is alkyl having from 1 to 3 carbon atoms; R 3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;
A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and
perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and
R 1 is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R 1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula I.

3. 发明授权

EP1416795B1 COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL DISEASES 有权
标题翻译：组合物和方法线粒体疾病的治疗
公开(公告)号：EP1416795B1
公开(公告)日：2012-10-31
申请号：EP02759363.1
申请日：2002-08-14
申请人： Wellstat Therapeutics Corporation
发明人： SAYDOFF, Joel, A.
IPC分类号： A61K31/70 , A61K31/197 , A61P25/14
CPC分类号： A61K31/197 , A61K31/70 , A61K2300/00

4. 发明公开

EP2295063A8 Compositions and the use thereof the treatment of mitochondrial diseases 有权
标题翻译：组合物及其用于线粒体疾病的治疗
公开(公告)号：EP2295063A8
公开(公告)日：2011-05-18
申请号：EP10184919.8
申请日：1999-08-31
申请人： Wellstat Therapeutics Corporation
发明人： Von Borstel, Reid, W
IPC分类号： A61K31/7068 , A61K31/7072 , A61P25/00
CPC分类号： A61K31/19 , A61K31/513 , A61K31/70 , A61K31/7068 , A61K31/7072 , C07H19/067 , A61K2300/00
摘要： There is provided a method for treating or preventing pathophysiological consequences of mitochondrial respiratory chain dysfunction in a mammal comprising administering to said mammal in need of such treatment or prevention an effective amount of a pyrimidine nucleotide. There is also provided a method for reducing side effects of cytotoxic cancer chemotherapy agents by administering a pyrimidine nucleotide precursor, where said cytotoxic chemotherapy agent is not a pyrimidine nucleoside analog.
摘要翻译：提供了用于治疗或预防哺乳动物线粒体呼吸链功能障碍的病理生理学后果的方法，其包括向需要这种治疗或预防的所述哺乳动物施用有效量的嘧啶核苷酸。还提供了通过施用嘧啶核苷酸前体来减少细胞毒性癌症化疗剂的副作用的方法，其中所述细胞毒性化疗剂不是嘧啶核苷类似物。

5. 发明授权

EP1633340B1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS 有权
公开(公告)号：EP1633340B1
公开(公告)日：2010-11-10
申请号：EP04759257.1
申请日：2004-04-08
申请人： Wellstat Therapeutics Corporation
发明人： HODGE, Kirvin, L. , SHARMA, Shalini , VON BORSTEL, Reid, W. , WOLPE, Stephen, D.
IPC分类号： A61K31/19 , A61K31/34 , A61K31/36 , A61P3/06 , A61P3/10 , A61P9/10 , A61P9/12
CPC分类号： A61K31/19 , A61K31/195 , A61K31/34 , A61K31/36 , A61K31/47
摘要： Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is 0 or 1; R2 is alkyl having from 1 to 3 carbon atoms; R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and 0 and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and R1 is hydrogen or alkyl having 1 or 2 carbon atoms, provided that when m is 0 or 1, R1 is not hydrogen. Alternatively, when R1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula I.

6. 发明公开

EP2026659A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS 审中-公开
标题翻译：用于治疗代谢性疾病的化合物
公开(公告)号：EP2026659A2
公开(公告)日：2009-02-25
申请号：EP07798274.2
申请日：2007-06-08
申请人： Wellstat Therapeutics Corporation
发明人： SHARMA, Shalini , VON BORSTEL, Reid W.
IPC分类号： A01N57/10 , A61K31/66
CPC分类号： A61K31/192 , A61K31/66 , C07C59/68
摘要： 3-(2,4-Bis(trifluoromethyl)benzyloxy)phenylacetic acid, 4-(2,6-Dimethylbenzyloxy)-phenylacetic acid, and their pharmaceutically acceptable salts are useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis.
摘要翻译： 3-（2,4-双（三氟甲基）苄氧基）苯乙酸，4-（2,6-二甲基苄氧基） - 苯基乙酸及其药学上可接受的盐可用于治疗各种代谢疾病，例如胰岛素抵抗综合征，糖尿病，多囊卵巢综合征，高脂血症，脂肪肝病，恶病质，肥胖症，动脉粥样硬化和动脉硬化。

7. 发明公开

EP1820805A3 Inhibitor and stimulator of haemotopoietic stem cell proliferation and uses thereof 失效
标题翻译：抑制剂和增殖造血干细胞及其应用的刺激
公开(公告)号：EP1820805A3
公开(公告)日：2007-11-07
申请号：EP05019956.1
申请日：1997-04-03
申请人： Wellstat Therapeutics Corporation
发明人： Wolpe, Stephen D. , Tsyrlova, Irena
IPC分类号： C07K14/00 , A61K38/19
CPC分类号： C07K14/52 , A61K38/00 , C07K14/475 , C07K14/805
摘要： Disclosed and claimed are methods for the isolation and use of stem cell modulating factors for regulating stem cell cycle and for accelerating the post-chemotherapy peripheral blood cell recovery. Also disclosed and claimed are the inhibitors and stimulators of stem cell proliferation.

8. 发明公开

EP1633340A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS 有权
标题翻译：用于治疗代谢性疾病的化合物
公开(公告)号：EP1633340A2
公开(公告)日：2006-03-15
申请号：EP04759257.1
申请日：2004-04-08
申请人： Wellstat Therapeutics Corporation
发明人： HODGE, Kirvin, L. , SHARMA, Shalini , VON BORSTEL, Reid, W. , WOLPE, Stephen, D.
IPC分类号： A61K31/19 , A61K31/34 , A61K31/36
CPC分类号： A61K31/19 , A61K31/195 , A61K31/34 , A61K31/36 , A61K31/47
摘要： Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is 0 or 1; R2 is alkyl having from 1 to 3 carbon atoms; R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and 0 and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and R1 is hydrogen or alkyl having 1 or 2 carbon atoms, provided that when m is 0 or 1, R1 is not hydrogen. Alternatively, when R1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula I.
摘要翻译：公开了用于治疗各种代谢疾病如胰岛素抵抗综合征，糖尿病，高脂血症，脂肪肝疾病，恶病质，肥胖症，动脉粥样硬化和动脉硬化的药物。其中n是1或2; m是0,1,2,3或4; q是0或1; t是0或1; R2是具有1至3个碳原子的烷基; R3为氢，卤素，具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基; A是未取代的或被1或2个选自以下的基团取代的苯基：卤素，具有1或2个碳原子的烷基，全氟甲基，具有1或2个碳原子的烷氧基和全氟甲氧基; 或具有3至6个环碳原子的环烷基，其中所述环烷基未被取代或者一个或两个环碳独立地被甲基或乙基单取代; 或具有1或2个选自N，S和O的环杂原子的5或6元杂芳族环，并且所述杂芳族环通过环碳与式I化合物的其余部分共价结合; 且R1是氢或具有1或2个碳原子的烷基，条件是当m为0或1时，R1不是氢。或者，当R 1是氢时，生物活性剂可以是式I化合物的药学上可接受的盐。

9. 发明授权

EP0679160B1 PYRIMIDINE NUCLEOTIDE PRECURSORS FOR TREATMENT OF INFLAMMATORY HEPATITIS 失效
标题翻译：嘧啶核苷酸PRE-治疗炎性甲型肝炎
公开(公告)号：EP0679160B1
公开(公告)日：2004-11-17
申请号：EP94903322.9
申请日：1993-12-01
申请人： Wellstat Therapeutics Corporation
发明人： VON BORSTEL, Reid, Warren , BAMAT, Michael, Kevin , HILTBRAND, Bradley, M.
IPC分类号： C07H19/067 , C07H19/167 , A61K31/70 , A61K31/515 , A61K31/505 , A61K31/715 , A61P1/16
CPC分类号： A61K31/715 , A61K31/00 , A61K31/505 , A61K31/513 , A61K31/515 , A61K31/70 , A61K31/7068 , A61K31/7072 , A61K31/7088 , A61K45/06 , C07H19/06 , A61K2300/00
摘要： Pyrimidine nucleotide precursors including acyl derivatives of cytidine, uridine, and orotate, and uridine phosphorylase inhibitors, and their use in enhancing resistance to sepsis or systemic inflammation are disclosed.

10. 发明公开

EP1461323A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS 有权
标题翻译：化合物的代谢疾病的治疗
公开(公告)号：EP1461323A2
公开(公告)日：2004-09-29
申请号：EP02744271.4
申请日：2002-06-12
申请人： Wellstat Therapeutics Corporation
发明人： SHARMA, Shalini , VON, Borstel, Reid, W. , HODGE, Kirvin, L. , BAMAT, Michael, K.
IPC分类号： C07D249/12 , C07D257/00 , C07C69/76 , C07C59/86 , C07C59/90 , C07C229/00
CPC分类号： C07B41/12 , A01N37/10 , A61K31/165 , A61K31/192 , A61K31/216 , A61K31/235 , A61K31/41 , A61K31/4196 , A61K31/44 , A61K31/445 , A61K31/535 , A61K31/54 , C07C59/68 , C07C59/90 , C07C67/47 , C07C69/738 , C07C209/68 , C07C217/22 , C07C233/31 , C07C233/47 , C07C235/78 , C07C235/84 , C07C259/06 , C07C323/52 , C07C323/59 , C07C2601/02 , C07C2601/04 , C07C2602/04 , C07D213/30 , C07D213/55 , C07D249/10 , C07D249/12 , C07D257/04 , C07D333/16 , C07D333/24 , Y10S514/866
摘要： Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式